RE:RE:Uddin's Comments on Buy ratingCancerSlayer wrote:
Kingpin68 wrote:
For the 27 subjects in TLTs pivotal trial to achieve the same CR rate at 360 days as Keytruda, an additional three subjects out of the 11 which had not received both doses of TLD-1433 would need to achieve CR representing a 27 per cent threshold (3/11) we believe this is a feasible threshold for Theralase given the data presented to date, Uddin said... As the Phase 2 pivotal trial continues to progress, we believe the results should elucidate the efficacy potential of TLT-1433. We are maintaining our SPECULATIVE BUY rating and a target price of $0.70, Uddin wrote.
The number of patients who had not received two doses at the 270 & 360 day marks would be 9 of the 27 total reported (not 11). The 270 & 360 day marks represent the % of patients who still have their data pending....the interim marks have nothing to do with the number of patients who have yet to receive their 2nd treatment. Patients 13, 14 & 15 all received their 1st treatment before 2/24/2021. So we have 3 patients from Ph 1b & the 15 patients from Ph 2 (a total of 18 of 27 patients) who would have received two treatments by now (at 0 & 180 days). The 27% threshold doesn't change, but we only need 3 of the remaining 9 to be CR at 360 days...all of whom will have received "two" optimized treatments. That would put us well above that 27% threshold.
I also maintain a STRONG SPECULATIVE BUY, but I won't dare try to put a target price on this one ; )
JMO. GLTA.
Sorry folks...meant to say the 27% threshold does change...it would be 33% for the remaining 9. Discard the highlighted statement...should have read "That would put us safely above Keytruda's 19% threshold". Ugh...back to sleep.